Crossmark

Immune checkpoint inhibitor-associated sick sinus syndrome and cardiogenic shock

Published Online: 2024-08-30

Authors

Kitano, Masatake

Yomota, Makiko https://orcid.org/0000-0002-1616-9893
Ito, Kansuke

Hosomi, Yukio
License Information

Text and Data Mining valid from 2024-08-30

Version of Record valid from 2024-08-30
More Information

Article History

Received: 10 May 2024

Accepted: 18 August 2024

First Online: 30 August 2024

Declarations

:

: Y. H. received honoraria (lecture fees) from AstraZeneca, Eli Lilly Japan, Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb, Kyowa Kirin, Nippon Kayaku, Takeda, Eisai, Novartis, Pfizer and MSD. M.Y. received honoraria (lecture fees) from AstraZeneca, Takeda, MSD, Chugai Pharmaceutical, Ono Pharmaceutical, and Bristol-Myers Squibb. M. K. received honoraria (lecture fees) from Chugai Pharmaceutical. The other authors declare that they have no conflicts of interest.

: Formal consent was not required for this study.

: Informed consent was obtained from the participant.

Document is current